Krebs Biochemicals & Industries Ratios

Krebs Biochemicals & Industries Ltd Ratios

The Krebs Biochemicals & Industries Ltd Ratios page provides a complete fundamental analysis of Krebs Biochemicals & Industries Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Krebs Biochemicals & Industries Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Krebs Biochemicals & Industries Ltd (NSE: KREBSBIO, BSE: 524518) is currently trading at ₹57.04, with a market capitalization of ₹1.25B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Krebs Biochemicals & Industries Ltd remains a key stock for fundamental analysis using Krebs Biochemicals & Industries Ltd Ratios.

Krebs Biochemicals & Industries Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Krebs Biochemicals & Industries Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Krebs Biochemicals & Industries Ltd Ratios.

Historically, the Krebs Biochemicals & Industries Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Krebs Biochemicals & Industries Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Krebs Biochemicals & Industries Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Krebs Biochemicals & Industries Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Krebs Biochemicals & Industries Ltd P/S ratio currently stands at 3.32, an important part of Krebs Biochemicals & Industries Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.32
• 2023: 2.61
• 2022: 2.31
• 2021: 5.11

The rising Krebs Biochemicals & Industries Ltd P/S ratio indicates improved revenue valuation by investors.

Krebs Biochemicals & Industries Ltd Price to Cash Flow Ratio (P/CF)

The Krebs Biochemicals & Industries Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Krebs Biochemicals & Industries Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The declining Krebs Biochemicals & Industries Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Krebs Biochemicals & Industries Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Krebs Biochemicals & Industries Ltd EV currently stands at ₹3.56B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 3.56B
• 2023: 3.25B
• 2022: 3.05B
• 2021: 4.52B

Krebs Biochemicals & Industries Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Krebs Biochemicals & Industries Ltd EV/EBITDA ratio is currently 0, a key metric in Krebs Biochemicals & Industries Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Krebs Biochemicals & Industries Ltd EV/EBITDA indicates balanced valuation.

Krebs Biochemicals & Industries Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Krebs Biochemicals & Industries Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Krebs Biochemicals & Industries Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Krebs Biochemicals & Industries Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Declining ROE indicates pressure on profitability.

Krebs Biochemicals & Industries Ltd Ratios Analysis Summary

The Krebs Biochemicals & Industries Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Krebs Biochemicals & Industries Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Krebs Biochemicals & Industries Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.